Inovio Launches Underwritten Offering of Common Stock and Warrants to Fund INO-3107 Launch Prep
INO is trading near its 52-week low of $0.95 (13% below the low).
Summary
Inovio launched an underwritten public offering of common stock and warrants, with preliminary Q2 cash of only $36.7 million. The highly dilutive raise is critical to fund preparations for a potential INO-3107 launch ahead of the October 30 PDUFA date. The offering priced at $0.95 per share for $20 million and is expected to close around July 31.
Updated with a Reuters report · What changed
Updates
· Reuters — INOVIO priced the offering at $0.95 per share, raising $20 million through 21.05 million shares and warrants, adding roughly 25% to outstanding shares. The offering is expected to close around July 31.
Key Events · Financing and Capital Events · INO
-
Updated · · Reuters
Underwritten Offering Priced at $0.95
Inovio is offering shares of common stock in fixed combinations with warrants (each share accompanied by a warrant to purchase two shares). The warrants are immediately exercisable with a five-year term. The offering priced at $0.95 per share, raising $20 million through 21.05 million shares and warrants, adding roughly 25% to outstanding shares, and is expected to close around July 31.
-
Preliminary Cash of $36.7M
As of June 30, 2026, Inovio estimates cash and cash equivalents of approximately $36.7 million, underscoring the urgent need for capital ahead of the October 30, 2026 PDUFA date for INO-3107.
-
Use of Proceeds
Net proceeds will be used primarily for preparing for a potential commercial launch of INO-3107, conducting a confirmatory trial if required, development of the clinical pipeline, and general corporate purposes.
-
Highly Dilutive Structure
The offering includes warrants to purchase two shares for each share sold, creating significant potential dilution. The deal is being executed near the 52-week low, reflecting the company's distressed financial position.
Analysis · INO · Life Sciences
Inovio is tapping its $300M shelf with an underwritten public offering of common stock and warrants. The deal is structured as fixed combinations of one share plus a warrant to buy two more shares, with the warrants immediately exercisable for five years. The company disclosed a preliminary cash balance of just $36.7 million as of June 30, 2026 — a razor-thin runway with the PDUFA date for its lead drug INO-3107 on October 30, 2026. Proceeds are earmarked for commercial launch preparation, a confirmatory trial if required, and pipeline development. The offering priced at $0.95 per share, raising $20 million through 21.05 million shares and warrants, adding roughly 25% to outstanding shares, and is expected to close around July 31. The offering is highly dilutive at current prices near the 52-week low, but the capital is essential to bridge the company to a potential approval. The warrant overhang and deeply discounted structure reflect the company's distressed position and urgent need for cash.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $0.95 to $2.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.